UNSPSC 51281611: Dihydrostreptomycin

This classification denotes an aminoglycoside antibiotic with the molecular formula C21H41N7O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P2I6R8W6UA, chemically known as streptomycin, dihydro- but generally known as dihydrostreptomycin, which bears US NIH Compound Identifier 31406. European Medicines Agency schedules Dihydrostreptomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07140MIG.

World Health Organization schedules dihydrostreptomycin in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, DIHYDROSTREPTOMYCIN remains the US FDA Preferred Term for this commodity. Dihydrostreptomycin bears US NLM identifiers UMLS ID C0262967 and NCI Concept Code C61724. SMILES: O(C1OC(C(O)(C1OC1OC(C(O)C(O)C1NC)CO)CO)C)C1C(/N=C(/N)N)C(O)C(/N=C(/N)N)C(O)C1O.

UNSPSC 51281611 Dihydrostreptomycin is a Commodity code with minimal alignment to recent state and local procurement activity. The code nominally covers a specific antibiotic pharmaceutical, but the recent opportunities posted under this code actually solicit naloxone and drug deactivation systems, prescription fulfillment programs, emergency medical supplies, and multi-source generic pharmaceuticals—none of which are dihydrostreptomycin or closely related products. State and local governments do procure pharmaceuticals and medical supplies through open competitive bidding, but the mismatch between the code name and the actual scope of work being bought suggests this code is either mis-tagged in these opportunities or sees inconsistent categorization across jurisdictions.

The issuing bodies span a county health department (Seminole County, Florida), a state health commission (Texas HHS Commission), a municipal fire department (City of Tampa), and a multi-state cooperative purchasing alliance (Minnesota MMCAP, serving state and local facilities across participating states including Oregon). Geographic activity appears concentrated in Florida, Texas, and the upper Midwest, though the cooperative vehicle serves a broader footprint. Representative opportunities include Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2023, with an estimated two-year contract and renewal option), the City of Tampa's ITB for medical and first aid supplies to the Fire Department Rescue Division (due March 13, 2026, estimated at $700,000, with a Small Local Business Enterprise set-aside and 5% bid discount), the Texas HHS Commission's RFI on direct-to-manufacturer prescription programs (response due April 3, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (proposals due March 26, 2026, for July 1, 2026 implementation across participating jurisdictions). The Tampa procurement specifies an SLBE preference; the MMCAP vehicle requires cGMP certification, DSCSA compliance, and relationships with designated wholesalers. No clear repeat buyers or concentrated procurement patterns emerge from the block.